Overview
ICON
Contract research organization (CRO) ICON is not iconic yet, but it would like to be. By the time a new drug hits the market, it has passed through a series of clinical trials to demonstrate its safety and effectiveness; guiding drugs through that process is what ICON does best. The company provides drugmakers and medical device companies around the world with a broad range of services for their product candidates' clinical trials. ICON designs
...
Read More studies and recruits investigators; manages and analyzes trial data; writes reports and other documents; and assists with regulatory filings. Spanning the full development cycle, it also helps with preclinical drug development and post-approval safety monitoring.
Read Less
Read More studies and recruits investigators; manages and analyzes trial data; writes reports and other documents; and assists with regulatory filings. Spanning the full development cycle, it also helps with preclinical drug development and post-approval safety monitoring.
Read Less
EUGENE PACELLI CAGUE
See more contacts
Scientific Research and Development Services
,
Architectural, Engineering, and Related Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
,
Testing laboratories
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
Estimated
$8.12 billion
Actual
1.99%
29.26%
$16,877
DEC
?
?
NASDAQ:ICLR
Contacts
Get in Touch with 10 Principals* and 2,341 Contacts
-
EUGENE PACELLI CAGUEDirector
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2023 (12 month period) in USD
Annual Revenue 2024
$8.12 billion
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $1,287 | $1,161 | $563 |
| Net Investing Cash | -$267 | -$227 | -$146 |
| Net Financing Cash | -$837 | -$844 | -$864 |
| Net Change in Cash | $183 | $90 | -$447 |
| Cash at Beginning of Period | $378 | $289 | $752 |
| Cash at End of Period | $539 | $378 | $289 |
| Capital Expenditure | -$168 | -$141 | -$142 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $539 | $378 | $289 |
| Accounts Receivable | $1,402 | $1,790 | $1,731 |
| Inventories | $ | $ | $ |
| Other Current Assets | $1,590 | $1,243 | $1,209 |
| Asset Summary | |||
| Total Current Assets | $3,530 | $3,411 | $3,229 |
| Tangible Fixed Assets | $530 | $502 | $504 |
| Intangible Assets | $3,560 | $3,856 | $4,279 |
| Total Assets | $16,878 | $16,990 | $17,185 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $705 | $595 | $611 |
| Short-Term Debt | $30 | $110 | $55 |
| Other Current Liabilities | $2,062 | $2,120 | $2,024 |
| Liability Summary | |||
| Total Current Liabilities | $2,796 | $2,826 | $2,691 |
| Long-Term Debt | $3,396 | $3,665 | $4,599 |
| Other Long-Term Liabilities | $83 | $46 | $25 |
| Total Liabilities | $7,355 | $7,749 | $8,687 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $7 | $7 | $7 |
| Retained Earnings | $2,725 | $2,434 | $1,821 |
| Equity Summary | |||
| Total Equity | $9,523 | $9,241 | $8,498 |
| Shares Outstanding | 80,756,860 | 82,495,086 | 81,723,555 |